Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Systemic Juvenile Idiopathic Arthritis (MRA316JP)
NCT00144599Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2004
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 3 trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Chugai Pharmaceutical Co., Ltd.. Started May 2004; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT00144599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144599.